Microbiotica nabs $67 million to expand its therapeutics pipeline

The biotechnology company records largest microbiome-based financing in Europe till date

England-based biotech company, Microbiotica, has reportedly secured $67 million in Series B financing round making it the largest investment in the field of microbiome therapeutics in Europe.

With expertise in discovery and development of microbiome-based therapeutics, the company’s recent investment round was co-led by Flerie Invest and Tencent.

The former is a leading Swedish life science investor seeking biotech companies with capabilities to counter critical medical challenges, whereas the latter is a global tech firm backing innovations that can better human life.

Moreover, the funding round also welcomed participation from new investors including British Patient Capital alongside existing investors IP Group, Cambridge Innovation Capital, and Seventure Partners - a prominent leading investor in life science microbiome developments.

The fresh capital will be focused in advancing Microbiotica’s discovery pipeline comprising of biomarkers and Leading Bacterial Therapeutics (LBTs) in new disease spaces.

Speaking on the latest accomplishment, Mike Romanos, Co-founder and CEO of Microbiotica, mentioned that the company will perform clinical trials for lead products in the immune-oncology and ulcerative colitis pipeline and further expand its microbiome-based therapeutics portfolio.

Microbiotica’s leading candidates for oral LBTs

MB097 and MB310 are the two key candidates for oral LBTs that will use the fresh investment to progress Phase 1b clinical studies.

MB097 is an LBT candidate consisting of a consortium of bacteria with Microbiotica’s clinical microbiome at the core analysing patient response to Immune Checkpoint Inhibitor therapy.

Meanwhile MB310 showcases similarity in terms of fully defined LBT with consortium of bacteria for Ulcerative Colitis (UC) treatment allowing remission during UC faecal transplant clinical trial.

MB097 as well as MB310 are precision medicines developed using clinical microbiome profiling with superior accuracy on Microbiotica’s platform which connects consortia of bacteria with data outcome from clinical studies.

As of now, both candidates have been validated and characterized pre-clinically via mechanical determination representing in vivo efficacy and ex vivo human cell data.

Source Credit: https://www.biospace.com/article/releases/microbiotica-raises-50m-67m-to-advance-pipeline-of-microbiome-based-therapeutics/